Deal overview
Gedeon Richter PLC has reached an agreement to acquire Mayne Pharma for A$604 million, or A$6.40 in cash per Mayne share, the companies said on Tuesday. The A$6.40 cash consideration equals a 99.4% premium to Mayne's closing share price on November 16 and values the transaction at roughly US$407 million.
Market reaction
Sydney-listed Mayne shares jumped sharply after the announcement, rising as much as 86.3% to A$5.98 by 00:51 GMT. That intraday move took the stock to its highest level since Nov, 2025.
Board recommendation and conditions
Mayne's board has unanimously recommended that shareholders vote in favour of the transaction, provided there is no superior proposal and subject to an independent expert concluding the deal is in the best interests of shareholders. The scheme is conditional on a number of approvals and actions, meaning completion is not guaranteed.
Financing and regulatory steps
Richter said the acquisition will be fully funded from its internal cash resources. The deal remains subject to regulatory approvals, shareholder and court approvals, and the completion of Mayne Pharma's previously announced sale of its international business to Evaris Pharma.
Timeline
The shareholder vote is expected to take place in late January 2027, and the companies are targeting completion of the transaction in March.
Strategic rationale cited by Richter
Richter indicated the acquisition would bolster its footprint in the United States, with particular emphasis on women's health and other therapeutic areas where Mayne has operations.
Clear summary
Gedeon Richter has agreed to buy Mayne Pharma for A$604 million - A$6.40 per share in cash - a bid that values Mayne at roughly US$407 million and represents a near-doubling premium to a mid-November closing price. The Mayne board supports the deal pending an independent expert opinion and in the absence of a better offer. Completion depends on regulatory, shareholder and court approvals and Mayne's divestment of its international business to Evaris Pharma. A shareholder vote is expected in late January 2027 with closing targeted for March.
Key points
- Acquisition price: A$604 million total consideration, A$6.40 per share in cash, a 99.4% premium to the November 16 close.
- Market impact: Mayne shares rose as much as 86.3% to A$5.98, the highest since Nov, 2025; Richter said it will fund the purchase from internal cash.
- Sector and market implications: The transaction affects the pharmaceutical and healthcare sectors, with implications for US women's health exposure and Australian equity markets.
Risks and uncertainties
- The deal is contingent on regulatory approvals, shareholder and court approvals, meaning it could be delayed or fail to complete.
- Completion also depends on Mayne finalising the previously announced sale of its international business to Evaris Pharma.
- Mayne's board recommendation is conditional - it is subject to no superior proposal emerging and to an independent expert determining the transaction is in shareholders' best interests.